Ramsay (ASX:RHC) share price finishes higher as COVID surgery restrictions ease

Life is slowing moving back to normal for Ramsay.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Ltd (ASX: RHC) share price surged throughout Wednesday. This comes as the private hospital operator provider made an important announcement to investors on the ASX.

At Wednesday's closing bell, Ramsay shares finished the day 0.81% higher to $67.29.

A patient in a hospital bed is reassured by a doctor.

Image source: Getty Images

What did Ramsay announce?

In its statement, Ramsay advised that the NSW Ministry of Health that is lifting restrictions on non-urgent elective surgery. The change is for all private and public facilities within Greater Sydney and will come into effect on 25 October.

Overnight elective surgery will be capped at 75% across the board. However, private facilities within this region can exceed the cap if they are providing surgery for public patients.

In addition, the Victorian Department of Health and Human Services also made some amendments to their policy for surgical operations. Last week, only category 1 and category 2 elective surgeries have been allowed to take place across private and public hospitals.

Day surgeries can be performed in metropolitan Melbourne. There are no current restrictions on public health services or public hospitals and emergency surgery.

While a weight has been lifted off Ramsay's shoulders, it noted there will be a material impact on its earnings for FY22. This is a result of surgical restrictions in Australia along with operating in a challenging COVID-19 environment.

About the Ramsay share price

It's been a bumpy road for Ramsay shares, navigating their way through persistent lockdowns and government-mandated restrictions. Certainly, the ASX Health Care Index (ASX: XHJ) has moved sideways since this time last year, up 1%.

When compared against the Ramsay share price, over the past 12 months, its shares have moved just 3.7% higher. However, when looking at year-to-date, its shares are up more than 8%.

Based on today's price, Ramsay commands a market capitalisation of roughly $15.4 billion and has 228.88 million shares on hand.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man clenches his fists with glee having seen the share price go up on the computer screen in front of him.
Healthcare Shares

Why this ASX biotech stock just rocketed 89% today

Immutep shares rocket after a fresh FDA win

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Orthocell shares soar 22% on landmark US breakthrough

The company has been given approval to sell Remplir in more than 220 hospitals in the US.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX biotech stock just jumped again as its lead drug trial moves ahead

The latest trial milestone sends this ASX biotech stock higher today.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Why are Telix shares sinking 7.5% today?

Let's see what this healthcare stock has announced today.

Read more »

A smiling businessman sits at a desk with bags of mony, indicating a share price rise after funding has been approved
Healthcare Shares

Telix Pharmaceuticals upsizes convertible bonds to US$600 million

Telix Pharmaceuticals has upsized its convertible bond issue to US$600 million, enhancing financial flexibility and repurchasing existing bonds.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Healthcare Shares

Telix Pharmaceuticals Investor Presentation: 56% FY25 revenue growth, pipeline advances

Telix Pharmaceuticals books 56% higher FY25 revenue, advances clinical pipeline, and issues upbeat FY26 guidance.

Read more »

A woman looks unimpressed on a blue background.
Healthcare Shares

What on earth's going on with CSL shares?

CSL’s growth slowed, and its premium valuation reset hard.

Read more »

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »